Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us ![]()
About
Not Confirmed
Not Confirmed
24-26 February, 2026
BIO Partnering at JPMBIO Partnering at JPM
Not Confirmed
Not Confirmed
12-15 January, 2026
Not Confirmed
Not Confirmed
17-21 January, 2026
List your booth number for exhibitions, ask us
CONTACT DETAILS






Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
24-26 February, 2026
BIO Partnering at JPMBIO Partnering at JPM
Industry Trade Show
Not Confirmed
12-15 January, 2026
Industry Trade Show
Not Confirmed
17-21 January, 2026
Digital content

10 Sep 2025
// INDPHARMAPOST
https://www.indianpharmapost.com/news/ichnos-glenmark-innovation-receives-upfront-payment-of-700-million-from-abbvie-17752

12 Jul 2025
// PRESS RELEASE
https://news.abbvie.com/2025-07-10-AbbVie-and-Ichnos-Glenmark-Innovation-IGI-Announce-Exclusive-Global-Licensing-Agreement-for-ISB-2001,-a-First-in-Class-CD38xBCMAxCD3-Trispecific-Antibody

02 Jun 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/06/02/3091923/0/en/Full-Dose-Escalation-Data-Show-Continued-High-Response-Rates-and-Favorable-Safety-Profile-of-ISB-2001-a-First-in-Class-BCMA-CD38-CD3-Trispecific-Antibody-for-the-Treatment-of-Relap.html

05 May 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/05/05/3073932/0/en/Ichnos-Glenmark-Innovation-IGI-Receives-U-S-FDA-Fast-Track-Designation-for-ISB-2001-for-Relapsed-Refractory-Multiple-Myeloma.html

05 Nov 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/11/05/2974962/0/en/Ichnos-Glenmark-Innovation-IGI-Announces-First-Presentation-of-Data-from-Phase-1-Study-of-the-Trispecific-ISB-2001-in-Relapsed-Refractory-Multiple-Myeloma-r-rMM-at-Upcoming-ASH-Ann.html
ABOUT THIS PAGE